Blab Tech
ARK Invest Sells 20 Stocks, Including Roku and 10x Genomics, as U.S. Markets End Higher
On Monday, U.S. equity markets closed broadly higher. The S&P 500 finished at 7,554.29, up 1.65 %. The Nasdaq Composite rose 3.07 % to 26,683.94, while the Dow Jones Industrial Average closed 0.92 % higher at 51,671.03. Technology shares were the main driver of the gains.
In the same trading session, Ark Invest, led by chief executive Cathie Wood, executed a large‑scale rebalancing of its portfolio. According to data from the brokerage platform moomoo, Ark sold positions in 20 different stocks across its funds. The most significant sell‑offs involved 665,000 shares of Roku Inc. (NASDAQ:ROKU), 535,000 shares of 10x Genomics Inc. (NASDAQ:TXG), and 526,000 shares of Strata Critical Medical (NASDAQ:SRTA). Other sales included shares of Pacific Biosciences of California, Amazon, Tesla, Advanced Micro Devices, Rocket Lab, SoFi Technologies, and Palantir.
The total volume of shares sold was substantial, but the exact dollar value of the transactions was not disclosed. The moves were reported by moomoo as part of a broader portfolio adjustment. Ark’s funds are actively managed exchange‑traded funds (ETFs) that focus on high‑growth technology and innovation sectors.
Roku, the U.S. streaming‑video platform, had been a core holding for Ark. The company’s stock had experienced a correction in recent months, and the sale of 665,000 shares represented a significant reduction in Ark’s exposure. 10x Genomics, a biotechnology firm that develops single‑cell sequencing technologies, was also a notable Ark holding. Ark’s sale of 535,000 shares of the company was the largest single‑stock transaction in the day.
Strata Critical Medical, a medical‑device manufacturer, was another Ark position that was liquidated. The company’s shares were sold in a block of 526,000 shares. Ark’s portfolio also included positions in other technology and biotech firms, such as Pacific Biosciences, Amazon, Tesla, AMD, Rocket Lab, SoFi Technologies, and Palantir. The sale of these shares suggests a shift in Ark’s allocation away from certain high‑growth areas.
Ark’s portfolio strategy has historically involved frequent rebalancing to maintain an optimal risk‑return profile. The firm’s public filings and statements indicate that it seeks to adjust holdings in response to market conditions and valuation changes. The recent sales are consistent with Ark’s past practice of rotating capital into new opportunities.
Market analysts have noted that the timing of the sales coincided with a broader rally in technology stocks. The Nasdaq’s 3.07 % gain was the strongest among the major indices for the day, and Ark’s portfolio adjustments were made in that context.
The sales were reported by moomoo, a brokerage platform that provides public trade data. Ark’s own disclosures, such as quarterly filings with the Securities and Exchange Commission, do not provide additional detail on the motivations behind the specific trades.
In the weeks leading up to the sale, Ark had made several other moves. The firm had increased positions in autonomous‑driving startups like Kodiak AI and Pony.ai, while reducing exposure to certain biotech and platform companies. The recent sale of Roku and 10x Genomics fits into this pattern of reallocating capital toward sectors Ark views as having higher growth potential.
As of the close of the trading day, Ark’s portfolio had shifted away from several high‑growth tech and biotech names. The firm’s next steps are not yet announced, but the sale of 20 stocks indicates a significant rebalancing effort. Investors and market watchers will likely monitor Ark’s subsequent filings for further changes.
In summary, Ark Invest sold large blocks of shares in 20 stocks, including 665,000 shares of Roku, 535,000 shares of 10x Genomics, and 526,000 shares of Strata Critical Medical, as part of a portfolio rebalancing. The U.S. equity markets closed higher, with technology stocks leading the rally. Ark’s moves are consistent with its active‑management strategy, but the firm has not publicly disclosed specific reasons for the sales.
In the same trading session, Ark Invest, led by chief executive Cathie Wood, executed a large‑scale rebalancing of its portfolio. According to data from the brokerage platform moomoo, Ark sold positions in 20 different stocks across its funds. The most significant sell‑offs involved 665,000 shares of Roku Inc. (NASDAQ:ROKU), 535,000 shares of 10x Genomics Inc. (NASDAQ:TXG), and 526,000 shares of Strata Critical Medical (NASDAQ:SRTA). Other sales included shares of Pacific Biosciences of California, Amazon, Tesla, Advanced Micro Devices, Rocket Lab, SoFi Technologies, and Palantir.
The total volume of shares sold was substantial, but the exact dollar value of the transactions was not disclosed. The moves were reported by moomoo as part of a broader portfolio adjustment. Ark’s funds are actively managed exchange‑traded funds (ETFs) that focus on high‑growth technology and innovation sectors.
Roku, the U.S. streaming‑video platform, had been a core holding for Ark. The company’s stock had experienced a correction in recent months, and the sale of 665,000 shares represented a significant reduction in Ark’s exposure. 10x Genomics, a biotechnology firm that develops single‑cell sequencing technologies, was also a notable Ark holding. Ark’s sale of 535,000 shares of the company was the largest single‑stock transaction in the day.
Strata Critical Medical, a medical‑device manufacturer, was another Ark position that was liquidated. The company’s shares were sold in a block of 526,000 shares. Ark’s portfolio also included positions in other technology and biotech firms, such as Pacific Biosciences, Amazon, Tesla, AMD, Rocket Lab, SoFi Technologies, and Palantir. The sale of these shares suggests a shift in Ark’s allocation away from certain high‑growth areas.
Ark’s portfolio strategy has historically involved frequent rebalancing to maintain an optimal risk‑return profile. The firm’s public filings and statements indicate that it seeks to adjust holdings in response to market conditions and valuation changes. The recent sales are consistent with Ark’s past practice of rotating capital into new opportunities.
Market analysts have noted that the timing of the sales coincided with a broader rally in technology stocks. The Nasdaq’s 3.07 % gain was the strongest among the major indices for the day, and Ark’s portfolio adjustments were made in that context.
The sales were reported by moomoo, a brokerage platform that provides public trade data. Ark’s own disclosures, such as quarterly filings with the Securities and Exchange Commission, do not provide additional detail on the motivations behind the specific trades.
In the weeks leading up to the sale, Ark had made several other moves. The firm had increased positions in autonomous‑driving startups like Kodiak AI and Pony.ai, while reducing exposure to certain biotech and platform companies. The recent sale of Roku and 10x Genomics fits into this pattern of reallocating capital toward sectors Ark views as having higher growth potential.
As of the close of the trading day, Ark’s portfolio had shifted away from several high‑growth tech and biotech names. The firm’s next steps are not yet announced, but the sale of 20 stocks indicates a significant rebalancing effort. Investors and market watchers will likely monitor Ark’s subsequent filings for further changes.
In summary, Ark Invest sold large blocks of shares in 20 stocks, including 665,000 shares of Roku, 535,000 shares of 10x Genomics, and 526,000 shares of Strata Critical Medical, as part of a portfolio rebalancing. The U.S. equity markets closed higher, with technology stocks leading the rally. Ark’s moves are consistent with its active‑management strategy, but the firm has not publicly disclosed specific reasons for the sales.
